NCT00032136已完成3 期
An Open Label, Randomized Multicenter Comparative Trial Of 5 Years Adjuvant Exemestane Treatment Versus 5 Years Adjuvant Tamoxifen Treatment In Postmenopausal Women With Early Breast Cancer
Cancer Research Campaign Clinical Trials Centre2 个研究点 分布在 1 个国家目标入组 4,400 人开始时间: 2001年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 4,400
- 试验地点
- 2
- 主要终点
- Relapse-free survival
研究概览
简要总结
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known if exemestane is more effective than tamoxifen in preventing the recurrence of breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have undergone surgery to remove early-stage breast cancer.
详细描述
OBJECTIVES:
- Compare the efficacy and tolerability of adjuvant exemestane versus adjuvant tamoxifen in postmenopausal women with early breast cancer.
- Compare the relapse-free survival and overall survival of patients treated with these drugs.
- Compare the incidence of contralateral breast cancer in patients treated with these drugs.
- Compare the safety and long-term tolerability of these drugs in these patients.
- Compare the quality of life of patients treated with these drugs.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to estrogen receptor (ER)/progesterone receptor (PgR) status (ER positive vs ER negative/PgR positive vs ER positive/PgR unknown), prior chemotherapy (none vs taxane-based vs anthracycline-based vs other), and nodal status (negative vs 1-3 nodes positive vs 4 or more nodes positive). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral tamoxifen once daily
- Arm II: Patients receive oral exemestane once daily. Treatment in both arms continues for a minimum of 5 years in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at months 3 and 12 during study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed early adenocarcinoma of the breast
- •Completely excised by surgery with curative intent (R0)
- •Any primary tumor greater than 3 cm OR
- •Any primary tumor grade III and greater than 1 cm
- •No positive supraclavicular nodes
- •Hormone receptor status:
- •Estrogen and/or progesterone receptor positive
- •PATIENT CHARACTERISTICS:
- •See Menopausal status
- •Menopausal status:
- •Postmenopausal
- •Any age with bilateral oophorectomy or amenorrhea for at least 5 years OR
- •Age 50 or over:
- •Natural amenorrhea for at least 1 year OR
- •Chemotherapy-induced amenorrhea for at least 2 years OR
- •Radiation-induced amenorrhea (at least 3 months since prior radiotherapy) OR
- •Under age 50:
- •If amenorrheic for less than 5 years (any cause) or prior hysterectomy without bilateral surgical oophorectomy, follicle-stimulating hormone must be assayed to confirm postmenopausal status
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Platelet count greater than 100,000/mm3
- •WBC greater than 3,000/mm3
- •SGOT or SGPT less than 2.5 times upper limit of normal (ULN)
- •Creatinine less than 1.5 times ULN
- •Cardiovascular:
- •No uncontrolled cardiac disease
- •No unstable angina
- •No congestive heart failure or arrhythmia requiring medical therapy
- •No myocardial infarction within the past 3 months
- •No severe osteoporosis
- •No other malignancies within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer
- •No other serious concurrent disease that would preclude study
- •No psychiatric disorders that would preclude study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •No prior neoadjuvant chemotherapy
- •No more than 10 weeks since completion of prior adjuvant chemotherapy
- •Endocrine therapy:
- •No prior adjuvant hormonal therapy for breast cancer
- •No prior neoadjuvant hormonal therapy (prior to surgery) for duration of more than 4 weeks
- •At least 4 weeks since prior hormone replacement therapy
- •Radiotherapy:
- •Not specified
- •See Disease Characteristics
- •No more than 10 weeks since completion of curative surgery
- 另有 2 项未显示
排除标准
- 未提供
结局指标
主要结局
Relapse-free survival
次要结局
- Overall survival
- Incidence of second breast cancer in contralateral breast
- Safety and long term tolerability
- Quality of life
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of TamoxifenBreast CancerNCT00016432NSABP Foundation Inc1,598
已完成
3 期
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerBreast CancerNCT00066573NCIC Clinical Trials Group7,576
已完成
2 期
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast CancerBreast CancerNCT00010010NYU Langone Health
已完成
3 期
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast CancerBreast CancerNCT00002777European Organisation for Research and Treatment of Cancer - EORTC342
Unknown
3 期
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast CancerBreast CancerNCT00003418International Collaborative Cancer Group4,400